Washington, DC – According to filings with the U.S. Securities and Exchange Commission, Cyrano Therapeutics is raising $12,804,250.00 in new funding. Sources indicate as part of senior management President, Richard Geoffrion played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Cyrano Therapeutics

Cyrano is developing an intranasal spray with the potential to treat and restore Smell and Flavor function. The Cyrano team has developed a unique, proprietary intranasal product to restore function in patients with a chronic loss of taste and smell. This is a condition affecting at least 14 million people in the US and a similar number in Europe, having a significant impact on safety, quality of life and well-being. Currently no marketed therapy exists and aside from the Cyrano product, none are in the pipeline. Cyrano has established the IP estate with the assistance of Wilson Sonsini. Key patents have been issued.

To learn more about Cyrano Therapeutics, visit http://cyranotherapeutics.com/

Contact:
Richard Geoffrion, President
925-822-6461
https://www.linkedin.com/in/rick-geoffrion-64b11b2/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved